Portal vein stenting to treat malignant portovenous obstruction: a multicentre retrospective analysis

Objectives Portal vein (PV) stenting has emerged as a treatment for malignant PV obstruction with the potential to improve symptoms of portal hypertension. However, data on outcomes and optimal antithrombotic management remain limited. Methods We conducted a retrospective multicentre study including patients treated with PV stenting for malignant obstruction at two tertiary centres in the Netherlands. The study outcomes included technical and radiological success, complications, number of reinterventions, survival and stent patency. Antithrombotic regimens were recorded descriptively. Results A total of 54 patients with malignant PV obstruction were included, most commonly due to pancreatic carcinoma (57.4%) and biliary tract cancer (33.3%). The technical success rate was 94.4%. Procedure-related complications occurred in 9.6% of patients and included vascular perforation, bleeding and unintended catheterisation of adjacent vessels. Median overall survival was 8.5 months (95% CI 6.4 to 11.1) with an estimated 1-year survival rate of 30.8% (95% CI 20.0% to 47.4%). At 6 and 12 months, the cumulative incidence of stent occlusion was 27.6% (95% CI 15.1% to 40.1%) and 38.5% (95% CI 24.6% to 52.4%), corresponding to patency rates of 72.4% and 61.5%, respectively. Antithrombotic treatment regimens varied considerably between patients. Conclusions PV stenting for malignant obstruction is technically feasible with a high success rate and acceptable safety profile in a palliative setting. However, procedural complications do occur and antithrombotic management is highly variable. Further prospective studies are needed to optimise postprocedural management and evaluate its impact on stent patency and clinical outcomes.

Authors

Institutions

Publication Details

Journal
BMJ Supportive & Palliative Care
Published
2026-11-18
DOI
https://doi.org/10.1136/spcare-2026-006622
Primary Topic
Abdominal vascular conditions and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Portal vein stenting to treat malignant portovenous obstruction: a multicentre retrospective analysis

Fenna A. van der Zijden, Martijn Ruben Meijerink, Bas Groot Koerkamp, Eric C. T. Geijteman et al.
BMJ Supportive & Palliative Care
Abdominal vascular conditions and treatments
article

Portal vein stenting to treat malignant portovenous obstruction: a multicentre retrospective analysis

Fenna A. van der Zijden, Martijn Ruben Meijerink, Bas Groot Koerkamp, Eric C. T. Geijteman, IJsbrand A.J. Zijlstra, Jessica J. Holster, Joris I. Erdmann, Diederik C. Bijdevaate, Kay J. Pieterman, Marjolein Homs, Anne Maas, Victor Van De Wiel
article en

Abstract

Objectives Portal vein (PV) stenting has emerged as a treatment for malignant PV obstruction with the potential to improve symptoms of portal hypertension. However, data on outcomes and optimal antithrombotic management remain limited. Methods We conducted a retrospective multicentre study including patients treated with PV stenting for malignant obstruction at two tertiary centres in the Netherlands. The study outcomes included technical and radiological success, complications, number of reinterventions, survival and stent patency. Antithrombotic regimens were recorded descriptively. Results A total of 54 patients with malignant PV obstruction were included, most commonly due to pancreatic carcinoma (57.4%) and biliary tract cancer (33.3%). The technical success rate was 94.4%. Procedure-related complications occurred in 9.6% of patients and included vascular perforation, bleeding and unintended catheterisation of adjacent vessels. Median overall survival was 8.5 months (95% CI 6.4 to 11.1) with an estimated 1-year survival rate of 30.8% (95% CI 20.0% to 47.4%). At 6 and 12 months, the cumulative incidence of stent occlusion was 27.6% (95% CI 15.1% to 40.1%) and 38.5% (95% CI 24.6% to 52.4%), corresponding to patency rates of 72.4% and 61.5%, respectively. Antithrombotic treatment regimens varied considerably between patients. Conclusions PV stenting for malignant obstruction is technically feasible with a high success rate and acceptable safety profile in a palliative setting. However, procedural complications do occur and antithrombotic management is highly variable. Further prospective studies are needed to optimise postprocedural management and evaluate its impact on stent patency and clinical outcomes.

BMJ Supportive & Palliative Care
Maastricht University Medical Centre (NL), Erasmus MC (NL), Erasmus MC Cancer Institute (NL), Amsterdam University Medical Centers (NL)
Good health and well-being
Abdominal vascular conditions and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon